This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 May 9;317(18):1835-1837.

doi: 10.1001/jama.2017.3436.

Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies

Jacob Kaufman¹, Thomas E Stinchcombe²

Affiliations

PMID: 28492885
DOI: 10.1001/jama.2017.3436

Editorial

Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies

Jacob Kaufman et al. JAMA. 2017.

. 2017 May 9;317(18):1835-1837.

doi: 10.1001/jama.2017.3436.

Authors

Jacob Kaufman¹, Thomas E Stinchcombe²

Affiliations

¹ Department of Medicine, Duke University, Durham, North Carolina.
² Duke Cancer Institute, Durham, North Carolina.

PMID: 28492885
DOI: 10.1001/jama.2017.3436

No abstract available

PubMed Disclaimer

Comment on

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Jänne PA, et al. JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438. JAMA. 2017. PMID: 28492898 Free PMC article. Clinical Trial.

Similar articles

In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.
Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA. Wagner PL, et al. Am J Clin Pathol. 2009 Oct;132(4):500-5. doi: 10.1309/AJCPF10ZUNSOLIFG. Am J Clin Pathol. 2009. PMID: 19762526
T-Cell Transfer Therapy Targeting Mutant KRAS.
Rech AJ, Vonderheide RH. Rech AJ, et al. N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637. N Engl J Med. 2017. PMID: 28207208 No abstract available.
The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.
Tímár J. Tímár J. Curr Opin Oncol. 2014 Mar;26(2):138-44. doi: 10.1097/CCO.0000000000000051. Curr Opin Oncol. 2014. PMID: 24463346 Review.
A step towards treating KRAS-mutant NSCLC.
Goldberg SB, Schlessinger J, Boyer JL, Herbst RS. Goldberg SB, et al. Lancet Oncol. 2013 Jan;14(1):3-5. doi: 10.1016/S1470-2045(12)70528-4. Epub 2012 Nov 28. Lancet Oncol. 2013. PMID: 23200176 No abstract available.
KRAS mutations in non-small cell lung cancer.
Riely GJ, Marks J, Pao W. Riely GJ, et al. Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5. doi: 10.1513/pats.200809-107LC. Proc Am Thorac Soc. 2009. PMID: 19349489 Review.

See all similar articles

Cited by

Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma.
Deng H, Liu H, de Silva T, Xue Y, Mohamud Y, Ng CS, Qu J, Zhang J, Jia WWG, Lockwood WW, Luo H. Deng H, et al. Mol Ther Oncolytics. 2019 Jul 23;14:266-278. doi: 10.1016/j.omto.2019.07.003. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31463367 Free PMC article.
TTF-1 and EGFR expression are related to EGFR mutation in lung adenocarcinoma.
Chen C, Shen D, Li J, Sun Y, Wang J. Chen C, et al. Int J Clin Exp Pathol. 2018 Sep 1;11(9):4650-4656. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31949865 Free PMC article.
Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
Gu G, Liu C, Zhu X, Yang Y, Song S, Zhao Y, Sun G. Gu G, et al. J Cancer Res Clin Oncol. 2024 Sep 7;150(9):413. doi: 10.1007/s00432-024-05932-x. J Cancer Res Clin Oncol. 2024. PMID: 39244518 Free PMC article.
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients.
Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A. Masykura N, et al. Lung Cancer (Auckl). 2019 Jun 17;10:57-66. doi: 10.2147/LCTT.S180692. eCollection 2019. Lung Cancer (Auckl). 2019. PMID: 31354372 Free PMC article.
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Sen M, Kindsfather A, Danilova L, Zhang F, Colombo R, LaPorte MG, Kurland BF, Huryn DM, Wipf P, Herman JG. Sen M, et al. Epigenetics. 2020 Jun-Jul;15(6-7):604-617. doi: 10.1080/15592294.2019.1676597. Epub 2019 Oct 13. Epigenetics. 2020. PMID: 31595832 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal